You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 1356 DM926, a novel anti-LILRB1/LILRB2 dual antagonist antibody, promotes adaptive and innate immune response to enhance anti-tumor activity in preclinical models

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Novel Single-Agent Immunotherapies
1356 DM926, a novel anti-LILRB1/LILRB2 dual antagonist antibody, promotes adaptive and innate immune response to enhance anti-tumor activity in preclinical models

 

Online download statistics by month:

Online download statistics by month: November 2023 to June 2025

AbstractFullPdf
Nov 2023162019
Dec 2023108020
Jan 20244907
Feb 20247002
Mar 20247605
Apr 20245007
May 202484022
Jun 20244602
Jul 20243605
Aug 20244407
Sep 20243601
Oct 202428010
Nov 20243208
Dec 20243008
Jan 20252605
Feb 2025809
Mar 2025004
Apr 2025006
May 2025003
Jun 2025002
Total8850152